Loading clinical trials...

To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE3

To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients

4week, a Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients

NCT03655210•Hanlim Pharm. Co., Ltd.

View on ClinicalTrials.gov

Summary

4week, a Multicenter, Randomized, Double-blinded, Parallel, Therapeutic confirmatory Clinical Trial

Detailed Description

4week, a Multicenter, Randomized, Double-blinded, Parallel, Therapeutic confirmatory Clinical Trial to Evaluate the Efficacy and Safety of HL151 versus Placebo in perennial allergic rhinitis patients

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Both gender, 19 years ≤ age
•2. At least two years history of allergic rhinitis prior to participate in clinical trial
•3. Patients with positive reaction for perennial allergen in tests(prick test or Intradermal test or MAST(Multiple Allergen Simultaneous Test) or Immuno CAP test) within 12 months
•4. In visit 2, patients with over mean 5 points of the total reflective TNSS score per day (during the run-in period) (highest value 12 points)
•5. Patients who can ability to record subject diary
•6. Patients who agreed to maintain the same environment throughout the entire clinical trial period.
•7. Written consent voluntarily to participate in this clinical trial after understanding and detailed explanation about this clinical trial

Exclusion Criteria

•1. Patients with non-allergic rhinitis
•2. Patients with asthma due to the following diseases(but patients with mild and intermittent asthma are available to participate in clinical trials)
•* Within four weeks from the date of screening, patients who visit the emergency room or have been hospitalized within 12 weeks or
•* patients with asthma who need other treatment except short-acting Beta-efficient respiratory relaxants Inhalation
•3. Patients with obstructive nasal polyp or severe deviated nasal septum
•4. Patients who Within 12 weeks from the date of screening, had damage or surgery around nasal cavity
•5. Patients with anamnesis in acute /chronic sinusitis

Locations (1)

Seoul National University Hospital

Gyeonggi-do, South Korea

Key Dates

Start Date

February 7, 2017

Primary Completion Date

February 20, 2017

Completion Date

October 16, 2017

Last Updated

August 31, 2018

Enrollment

272

ACTUAL participants

Conditions

Perennial Allergic Rhinitis

Interventions

HL151

DRUG

placebo

DRUG

A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

NCT01425632

Perennial Allergic Rhinitis

View study

TERMINATEDPHASE3

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

NCT04874714

Allergic RhinoconjunctivitisPerennial Allergic Rhinitis+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 31, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients

Inclusion Criteria

Exclusion Criteria

A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

NasoNeb Delivery of an Intranasal Steroid

A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)

Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis